Gastric CancerNCT07565818
Spectral CT Combined With MSI for Predicting Regional Lymph Node Metastasis in Gastric Cancer
A study testing o explore the value of spectral CT in the diagnosis and treatment of gastric cancer with different MSI statuses in people with Gastric Cancer, run by Yunnan Cancer Hospital at 1 site in China.
Trial summary
This study prospectively collected spectral CT imaging data and clinical information related to gastric cancer, evaluated the diagnostic efficacy of its image quality for regional lymph nodes in gastric cancer, and explored its application value in the N staging of gastric cancer with different MSI statuses, so as to… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Gastric Cancer
- What is being tested?
- o explore the value of spectral CT in the diagnosis and treatment of gastric cancer with different MSI statuses
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 260 participants
- Where
- 1 siteChina
- Study dates
- 4 Aug 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- (a)Patients with gastric adenocarcinoma confirmed by histopathological biopsy and definite microsatellite status determined by immunohistochemistry (IHC);
- (b)Abdominal dual-phase Quark CT scanning was performed within 2 weeks before surgery;
- (c)aged ≥ 18 years old
Who cannot join
- (a)Combined with other primary tumors;
- (b) The image quality does not meet the diagnostic criteria;
- (c)Those who cannot tolerate CT examination.
Trial locations and contacts
1 site in 1 country.
About this study
This study prospectively collected spectral CT imaging data and clinical information related to gastric cancer, evaluated the diagnostic efficacy of its image quality for regional lymph nodes in gastric cancer, and explored its application value in the N staging of gastric cancer with different MSI statuses, so as to provide a more accurate evidence for clinical diagnosis, promote the development of individualized treatment for gastric cancer, and ultimately improve the prognosis of patients.
- Conditions
- Gastric Cancer
- Being tested
- o explore the value of spectral CT in the diagnosis and treatment of gastric cancer with different MSI statuses
- Medical subject headings
- Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
o explore the value of spectral CT in the diagnosis and treatment of gastric cancer with different MSI statusesDiagnostic test
Abdominal CT scans were performed in addition to conventional treatment regimens
| Study group | Role | What they receive |
|---|---|---|
| Spectral CT combined with MSI for predicting regional lymph node metastasis in gastric cancer | Experimental | Medical images and clinical data related to gastric cancer were prospectively collected using a Philips Quark CT scanner, and its diagnostic accuracy and clinical application value in gastric cancer patients with different MSI statuses were evaluated to achieve accurate staging of gastric cancer. Patients diagnosed with gastric cancer at Yunnan Cancer Hospital from August 2025 to December 2026 were consecutively enrolled. After undergoing Philips Quark CT scanning, the N stage of gastric cancer was independently assessed by two radiologists, and statistical analysis was subsequently performed for the final results. Receives: Diagnostic Test: o explore the value of spectral CT in the diagnosis and treatment of gastric cancer with different MSI statuses |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pathological N stage
The lymph node status confirmed by surgical pathology was used as the reference standard
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2026
- Study start4 Aug 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 260 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Yunnan Cancer Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ye Lianhua, Study Director, Study director, Ethics Committee of Yunnan Provincial Cancer Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07565818
- Sponsor's protocol ID
- KYLX2025-296
- Status last verified
- Dec 2025
- First submitted
- 27 Apr 2026
- Last updated
- 4 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Spectral CT Combined With MSI for Predicting Regional Lymph Node Metastasis in Gastric Cancer
- ClinicalTrials.gov ID
- NCT07565818
- Acronym / sponsor ID
- KYLX2025-296
- Conditions
- Gastric Cancer
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 260 participants (estimated)
- Lead sponsor
- Yunnan Cancer HospitalUniversity, hospital or other
- Study start
- 4 Aug 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 4 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study prospectively collected spectral CT imaging data and clinical information related to gastric cancer, evaluated the diagnostic efficacy of its image quality for regional lymph nodes in gastric cancer, and explored its application value in the N staging of gastric cancer with different MSI statuses, so as to provide a more accurate evidence for clinical diagnosis, promote the development of individualized treatment for gastric cancer, and ultimately improve the prognosis of patients.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Spectral CT combined with MSI for predicting regional lymph node metastasis in gastric cancer | Experimental | Diagnostic Test: o explore the value of spectral CT in the diagnosis and treatment of gastric cancer with different MSI statusesMedical images and clinical data related to gastric cancer were prospectively collected using a Philips Quark CT scanner, and its diagnostic accuracy and clinical application value in gastric cancer patients with different MSI statuses were evaluated to achieve accurate staging of gastric cancer. Patients diagnosed with gastric cancer at Yunnan Cancer Hospital from August 2025 to December 2026 were consecutively enrolled. After undergoing Philips Quark CT scanning, the N stage of gastric cancer was independently assessed by two radiologists, and statistical analysis was subsequently performed for the final results. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- (a)Patients with gastric adenocarcinoma confirmed by histopathological biopsy and definite microsatellite status determined by immunohistochemistry (IHC);
- (b)Abdominal dual-phase Quark CT scanning was performed within 2 weeks before surgery;
- (c)aged ≥ 18 years old
Key exclusion criteria (3 listed)
- (a)Combined with other primary tumors;
- (b) The image quality does not meet the diagnostic criteria;
- (c)Those who cannot tolerate CT examination.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| o explore the value of spectral CT in the diagnosis and treatment of gastric cancer with different MSI statusesAbdominal CT scans were performed in addition to conventional treatment regimens | Diagnostic test | Spectral CT combined with MSI for predicting regional lymph node metastasis in gastric cancer |
Primary outcome
Pathological N stage
Time frame: 1 day
The lymph node status confirmed by surgical pathology was used as the reference standard
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2026.
Related trials for Gastric Cancer
Not yet recruitingPhase 1
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
Hepatocellular Carcinoma, Renal Cell Carcinoma
Recruiting
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Ampulla of Vater Carcinoma, Appendix Carcinoma
Not yet recruitingObservational study
Lymph Node Metastasis Pattern After Neoadjuvant Chemoimmunotherapy in LAGC
Stomach Neoplasms, Gastric Cancer (Diagnosis)
RecruitingPhase 2/3
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
Recruiting
Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ye Lianhua, Study Director study director
Ethics Committee of Yunnan Provincial Cancer Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing o explore the value of spectral CT in the diagnosis and treatment of gastric cancer with different MSI statuses in people with Gastric Cancer, run by Yunnan Cancer Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pathological N stage (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.